Cytokinetics (CYTK) P/B ratio

P/B ratio · fiscal 2021
14.4×

The P/B ratio of Cytokinetics (CYTK) was 14.4× at the end of fiscal 2021 (December 31, 2021). That is 21.4% higher than the 11.8× of fiscal 2020. Figures as of 18 Nov 2026, 11:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio, fiscal 2021
14.4×
Change on fiscal 2020
+21.4%
Highest on record
14.4×fiscal 2021
Lowest on record
1.0×fiscal 2012
Fiscal years on record
102009–2021

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Cytokinetics P/B ratio, in more detail

Across the 10 fiscal year-ends on record (2009–2021), the highest was 14.4× in fiscal 2021 and the lowest 1.0× in fiscal 2012.

History · 10 fiscal years

P/B ratio at each fiscal year-end

Cytokinetics P/B ratio, year by year

Cytokinetics (CYTK) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
2025——$63.54-$5.49
2024——$47.04-$1.21
2023——$83.49-$4.00
2022——$45.82-$1.20
202114.4× 21.4% up$45.58$3.17
202011.8×—$20.78$1.75
2019——$10.61—
2018——$6.32—
20173.7× 33.1% down$8.15$2.22
20165.5× 7.4% down$12.15$2.22
20155.9× 90.5% up$10.46$1.77
20143.1×—$8.01$2.58
2013——$6.50—
20121.0× 27.5% down$3.96$3.87
20111.4× 25.8% down$5.76$4.08
20101.9× 14.4% up$12.54$6.59
20091.7×—$17.46$10.50
2008——$17.10—
2007——$28.38—
2006——$44.88—
2005——$39.12—
2004——$61.50—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

P/B ratio at health care companies of similar size

P/B ratio of Cytokinetics and comparable companies
CompanyP/B ratio
Alkermes ALKS4.2×
PACS Group PACS8.1×
Kiniksa Pharmaceuticals International KNSA13.2×

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

More on CYTK

Cytokinetics, figure by figure

Cytokinetics (CYTK) overview: price, valuation and scorecardAll health care companies by market value

Cytokinetics P/B ratio: questions and answers

What is Cytokinetics's P/B ratio?

The P/B ratio of Cytokinetics (CYTK) was 14.4× at the end of fiscal 2021 (December 31, 2021). That is 21.4% higher than the 11.8× of fiscal 2020.

What are the highest and lowest P/B ratio figures on record for Cytokinetics?

Across the 10 fiscal year-ends on record (2009–2021), the highest was 14.4× in fiscal 2021 and the lowest 1.0× in fiscal 2012.

How is Cytokinetics's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Cytokinetics it is on record here for 10 fiscal years, 2009 to 2021.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Cytokinetics (CYTK) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CYTK/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.